Table 1

Base-case annual probabilities associated with LAM-resistant CHB
Initial state Entered state HBeAg (+) HBeAg (−) Source
Estimate (%) Range (%) Estimate (%) Range (%)
Lamivudine-resistant CHB Compensated cirrhosis 2.7 1.6-3.8 6.2 2.8-9.7 [27]
Hepatocellular carcinoma 0.4 0.3-0.6 0.4 0.3-0.6 [27]
Virological response Compensated cirrhosis 0.5 0.3-0.8 1.2 0.7-2 [25]
Hepatocellular carcinoma 0.2 0.1-0.4 0.2 0.1-0.4 [25]
Multi-resistant CHB Compensated cirrhosis 2.7 1.6-3.8 6.2 2.8-9.7 [27]
Hepatocellular carcinoma 0.4 0.3-0.6 0.4 0.3-0.6 [27]
Compensated cirrhosis Decompensated cirrhosis 7.3 3.5-10 7.3 3.5-10 [28]
Hepatocellular carcinoma 3.4 1-10 3.4 1-10 [28]
Death 4.9 2-14 4.9 2-14 [28]
Decompensated cirrhosis Hepatocellular carcinoma 3.4 1-10 3.4 1-10 [28]
Liver transplantation 5 1-10 5 1-10 [5]
Death 14.4 10-20 14.4 10-20 [5]
Hepatocellular carcinoma Liver transplantation 5 1-10 5 1-10 [5]
Death 23.3 20-30 23.3 20-30 [5]
Liver transplantation Death 7 2-12 7 2-12 [5]

CHB, chronic hepatitis B.

Wu et al.

Wu et al. BMC Health Services Research 2012 12:385   doi:10.1186/1472-6963-12-385

Open Data